United States – October 27, 2026 -- Eagleview's aerial-derived property data now runs in more than 500 live integrations, with developers using it for online quoting, lead enrichment and pre-inspection tools across roofing, solar, building materials and property & casualty insurance.

A single address lookup or API call can return roof geometry, pitch and area, material type, condition score, age estimate, solar panel presence, structural characteristics, and risk scores for hazards such as hail and wildfire.

United States – October 27, 2026 -- Eagleview's 2D-to-3D pitch editor is now available directly inside Xactimate®, letting roofers and property claims adjusters build 3D roof sketches from a single entered pitch without leaving their estimating platform.

Single pitch input generates a full 3D roof sketch

Users add pitch information to a 2D roof diagram and convert it into a 3D sketch. Only one roof pitch must be entered. The tool calculates additional pitches automatically to complete the model.

ROCHESTER, N.Y. – October 27, 2026 -- Eagleview's AI-powered Horizon platform completed portfolio-wide wildfire damage assessments in minutes that previously took weeks, the company said at its Property Claims Leadership Forum in Half Moon Bay, where it also released a white paper on AI-driven underwriting and claims.

Rochester, N.Y. – October 27, 2026 -- Eagleview has responded to 17 severe weather events across 10 U.S. states since December 2025, as its Disaster Response Program (DRP) marks 25 years amid a sharp rise in billion-dollar climate disasters.

U.S. disaster counts run 2-3x above the long-term average

The U.S. recorded 28 major climate disasters in 2023, 17 in 2024 and 21 in 2025. NOAA puts the long-term average at roughly nine. Each of these events costs roughly $1 billion, and many, including forest fires, cost far more.

PONTE VEDRA – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has agreed to raise $3 million in gross proceeds from a single healthcare-focused institutional investor. Warrants could bring in about $5.8 million more if exercised in full for cash.

PARIS – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reported that its 12-lipoxygenase inhibitor CAD-1005 reduced new or worsening thrombotic events by more than 25 percentage points versus placebo in a Phase 2 trial in heparin-induced thrombocytopenia (HIT), with 50% of treated patients affected versus more than 75% on placebo. The data were presented as one of three late-breaking abstracts at the ISTH 2026 Congress in Paris.

Ponte Vedra, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has launched a structured process to secure out-licensing, portfolio monetization or co-development partners for its late-stage cardiovascular assets, after grouping them into a Cardiac Acute Critical Care Franchise.

The company is exploring development, licensing and commercialization deals for CAD-1005, frunexian and tecarfarin. It describes the approach as capital-efficient and says it is shifting to a partnership-driven business model.

PONTE VEDRA, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) is seeking out-licensing or co-development partners for CAD-1005, a 12-LOX inhibitor it describes as Phase 3-ready, after a competitor's late-stage trial in cardiac surgery-associated acute kidney injury (CSA-AKI) was discontinued for lack of efficacy.

PONTE VEDRA – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has launched a structured partnering process for three cardiovascular assets while holding about $4.2 million in cash, enough to fund operations only through the first quarter of 2027.

PONTE VEDRA, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reached agreement with the FDA on the primary endpoint and placebo-controlled design of its Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT). The agreement came at a Type D meeting held July 28, 2026.